Vor Biopharma (NASDAQ: VOR)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-08 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.610 | ||||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Vor Biopharma (NASDAQ: VOR) through any online brokerage.
Other companies in Vor Biopharma’s space includes: Impel Pharmaceuticals (NASDAQ:IMPL), Inozyme Pharma (NASDAQ:INZY), Ambrx Biopharma (NYSE:AMAM), Humanigen (NASDAQ:HGEN) and Fusion Pharmaceuticals (NASDAQ:FUSN).
The latest price target for Vor Biopharma (NASDAQ: VOR) was reported by JMP Securities on Friday, May 13, 2022. The analyst firm set a price target for 15.00 expecting VOR to rise to within 12 months (a possible 241.69% upside). 8 analyst firms have reported ratings in the last year.
The stock price for Vor Biopharma (NASDAQ: VOR) is $4.39 last updated May 23, 2022, 8:00 PM UTC.
There are no upcoming dividends for Vor Biopharma.
Vor Biopharma’s Q2 earnings are confirmed for Monday, August 8, 2022.
There is no upcoming split for Vor Biopharma.
Vor Biopharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.